Slunga L, Johnson O, Dahlén G H
Department of Internal Medicine, University Hospital, Umeå, Sweden.
Eur J Clin Pharmacol. 1992;43(4):369-73. doi: 10.1007/BF02220611.
Thirty-six patients with total serum cholesterol levels above 6.5 mmol/l and Lipoprotein(a) levels above 100 mg.l-1 were evaluated in a 24 week double-blind, placebo controlled, cross-over study to assess the possible changes in Lp(a) during treatment with the HMG CoA reductase inhibitor simvastatin. The median plasma Lp(a) increased from 359 to 464 mg.l-1 during simvastin treatment as compared to placebo (not significant). Individual changes in Lp(a) varied. In a multivariate linear regression analysis the individual change in Lp(a) was correlated with the baseline Lp(a) (r = 0.64), the change in serum triglycerides (r = 0.48) and the baseline apolipoprotein B (r = 0.36). Differences between the Lp(a) phenotypes may explain some of the varied Lp(a) responses. It appears that the effect of simvastatin on the Lp(a) level in individuals is usually insignificant, but in patients with a high Lp(a) simvastatin may further increase it.
在一项为期24周的双盲、安慰剂对照、交叉研究中，对36名总血清胆固醇水平高于6.5 mmol/l且脂蛋白(a)水平高于100 mg·l-1的患者进行了评估，以评估使用HMG CoA还原酶抑制剂辛伐他汀治疗期间脂蛋白(a)的可能变化。与安慰剂相比，辛伐他汀治疗期间血浆脂蛋白(a)中位数从359 mg·l-1增至464 mg·l-1（无显著差异）。脂蛋白(a)的个体变化各不相同。在多变量线性回归分析中，脂蛋白(a)的个体变化与基线脂蛋白(a)（r = 0.64）、血清甘油三酯变化（r = 0.48）和基线载脂蛋白B（r = 0.36）相关。脂蛋白(a)表型之间的差异可能解释了脂蛋白(a)反应的一些变化。辛伐他汀对个体脂蛋白(a)水平的影响通常不显著，但在脂蛋白(a)水平高的患者中，辛伐他汀可能会使其进一步升高。
